Alluvi, formerly BI 4744, represents a promising advance in obesity treatment. This dual stimulator targeting both GLP-1 and GIP targets demonstrates compelling results in patient studies, arguably surpassing existing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/